Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma
Prior to the advent of chimeric antigen receptor (CAR) T-cell therapy, patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) had poor outcomes, with median overall survival (OS) of only 3–11 months after discontinuing a Bruton’s tyrosine kinase inhibitor (BTKi).
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa